ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1925 • ACR Convergence 2022

    Characterizing Phenotypic Changes by SARS-CoV-2 Variant in Multisystem Inflammatory Syndrome in Children (MIS-C): A Single Institution Case Series

    Sandy D. Hong1 and Emma Leisinger2, 1University of Iowa Stead Family Children's Hospital, Iowa City, IA, 2University of Iowa, Iowa City, IA

    Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a severe hyper-inflammatory condition associated with a recent SARS-CoV-2 infection. Case reports began in April of 2020…
  • Abstract Number: 1865 • ACR Convergence 2022

    Internet-based Enrollment for Myositis Studies Utilizing Patient Self-reported Diagnostic Criteria

    Raisa Lomanto Silva1, Silvia Martinez Laverde1, Siamak Moghadam-Kia1, Nicole Neiman2, Dana Ascherman3, Chester Oddis3 and Rohit Aggarwal4, 1University of Pittsburgh Medical Center, Pittsburgh, PA, 2Division of Rheumatology and Clinical Immunology, Department of Medicine, Pittsburgh, PA, 3University of Pittsburgh, Pittsburgh, PA, 4Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Recruitment is a major challenge in myositis clinical studies, which is hindered by the rarity and heterogeneity of the disease. Internet-based clinical studies using…
  • Abstract Number: 1379 • ACR Convergence 2022

    Association of HLA Alleles with Specific Auto-antibodies in an Ancestrally Diverse Population of Childhood Systemic Lupus Erythematosus (SLE)

    Nicholas Gold1, Fangming Liao1, JingJing Cao1, Daniela Dominguez1, Andrea Knight2, Deborah Levy3 and Linda Hiraki4, 1The Hospital for Sick Children, Toronto, ON, Canada, 2The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 4The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease capable of affecting multiple organ systems. Genetic variants in the Human Leukocyte Antigen (HLA) are associated…
  • Abstract Number: 1385 • ACR Convergence 2022

    Clinical and Serologic Characterization of Juvenile Systemic Sclerosis Overlap Disease

    Amanda Robinson and Kathryn Torok, Pediatric Rheumatology, Children's Hospital of UPMC, Pittsburgh, PA

    Background/Purpose: Juvenile systemic sclerosis (jSSc) is a systemic fibroinflammatory autoimmune disease characterized by skin fibrosis and multiple extracutaneous manifestations. A proportion of children with jSSc…
  • Abstract Number: 1862 • ACR Convergence 2022

    Lenabasum Reduces IFNγ and pIRF3 in Dermatomyositis Skin: Biomarker Results from a Double-Blind Phase 3 International Randomized Controlled Trial

    Thomas Vazquez1, Meena Sharma1, Rui Feng2, DeAnna Diaz3, Nilesh Kodali1, Josh Dan3, Madison Grinnell3, Emily Keyes3, Grant Sprow3, Barbara White4 and Victoria Werth3, 1Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, 3Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 4Corbus Pharmaceuticals, Pleasanton, CA

    Background/Purpose: Dermatomyositis (DM) is an autoimmune connective tissue disease that primarily affects the skin and lung; few effective treatment options are available. Lenabasum is a…
  • Abstract Number: 1941 • ACR Convergence 2022

    Pediatric Idiopathic Pulmonary Hemosiderosis – a Single-Center, Retrospective Study Comparing Use of Commonly Used Steroid-Sparing Agents

    Melissa Argraves1, Melissa Lerman1, Julie Chase2 and Samuel Goldfarb3, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Kentucky, Lexington, KY, 3University of Minnesota, Minneapolis, MN

    Background/Purpose: Idiopathic Pulmonary Hemosiderosis (IPH) is a rare, pediatric predominant condition causing episodic diffuse alveolar hemorrhage, which can be recurrent and life-threatening. Chronic steroid use…
  • Abstract Number: 1965 • ACR Convergence 2022

    Autoantibodies Against a Specific 25-mer Peptide from P. Gingivalis Are Present in Sera of Patients with Rheumatoid Arthritis and Early Arthritis

    Hsin-Yi Peng1, Ting-Yin Xue1, Fei-Hung Hsieh1, Yi-Ko Chen1, Mei-Chin Yin2, Che-Yi Chao2, Shu-Yao Tsai2, Chung-Ping Lin3, Po-Hao Huang3, Chien-Chung Huang3, Jiunn-Horng Chen3, Chung-Ming Huang3, Der-Yuan Chen4, Joung-Liang Lan5 and Gregory Tsay3, 1China Medical University, Taichung, Taiwan, 2Asia University, Taichung, Taiwan, 3China Medical University Hospital, Taichung, Taiwan, 4China Medical University Hospital Rheumatology and Immunology Center, Taichung, Taiwan, 5China Medoical University Hospital, Taichung, Taiwan

    Background/Purpose: The presence of rheumatoid factor (RF) or anti-cyclic citrullinated protein/peptide antibodies (ACPA) are included in the 2010 the ACR/EULAR classification criteria of rheumatoid arthritis…
  • Abstract Number: 1969 • ACR Convergence 2022

    The Potential Diagnostic Value of C-X-C Motif Chemokine 13 (CXCL13) in Seronegative Arthritis

    Silvia Piantoni1, Fabrizio Angeli1, Francesca Regola2, Franco Franceschini2 and Paolo Airò3, 1Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia, Italy, 2Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, 3Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy

    Background/Purpose: The finding of circulating biomarkers in the field of chronic arthritis is still an unmet need, especially for the subgroup of seronegative arthritis [e.g.,…
  • Abstract Number: 1967 • ACR Convergence 2022

    Sex Differences in Employment Outcomes in Patients with Recent Onset Rheumatoid Arthritis

    Carol Hitchon1, Marie-France Valois2, orit schieir2, Louis Bessette3, Gilles Boire4, Susan Bartlett5, Glen Hazlewood6, Edward Keystone7, Janet Pope8, Carter Thorne9, Diane Tin10 and Vivian Bykerk11, 1University of Manitoba, Winnipeg, MB, Canada, 2McGill University, Montréal, QC, Canada, 3Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, 4Universite de Sherbrooke, Sherbrooke, QC, Canada, 5McGill University, Montreal, QC, Canada, 6University of Calgary, Calgary, AB, Canada, 7Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 8University of Western Ontario, London, ON, Canada, 9Southlake Regional Health Centre, Newmarket, ON, Canada, 10The Arthritis Program Research Group, Newmarket, ON, Canada, 11Hospital for Special Surgery, New York, NY

    Background/Purpose: Early work cessation and reduced work and activity productivity are significant contributors to the personal and societal costs associated with rheumatoid arthritis (RA). We…
  • Abstract Number: 1950 • ACR Convergence 2022

    Morbidities Associated with Serious Infections in Patients with Rheumatoid Arthritis

    Bradly Kimbrough1, Cynthia Crowson2, Ryan Lennon3, John Davis3 and Elena Myasoedova3, 1Mayo Clinic Rochester, Rochester, MN, 2Mayo Clinic, Eyota, MN, 3Mayo Clinic, Rochester, MN

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for serious infections. Several infection risk scores have been developed over the last decade for…
  • Abstract Number: 1877 • ACR Convergence 2022

    Nailfold Videocapillaroscopic Abnormalities Correlate with Disease Activity Measures and Cutaneous Damage in Patients with Idiopathic Inflammatory Myopathies

    Diane Zisa1, Aliza Bloostein1, Deanna Jannat-Khah, DrPH, MSPH1, Maurizio Cutolo2, Vanessa Smith3 and David Fernandez1, 1Hospital for Special Surgery, New York, NY, 2Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy, 3Department of Rheumatology, Ghent University Hospital – Department of Internal Medicine, Ghent University, Belgium – Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Gent, Belgium

    Background/Purpose: Nailfold videocapillaroscopy (NVC) is a non-invasive tool used to evaluate the microcirculation of patients with connective tissue diseases (CTDs). A specific combination of NVC…
  • Abstract Number: 1881 • ACR Convergence 2022

    Association Study Between anti-TIF1γ Antibody and Development of Neoplasia in Three Tertiary Hospitals

    Marina Pavía Pascual1, Isidro Jarque Canalias1, Jose Luis Morell2, Jesús Loarce Martos3, Lorena Montaño Tapia4, Olga Rusinovich1, Natalia de la Torre-Rubio1, Maria Machattou1, Pablo Navarro Palomo1, Maria Carmen Barbadillo Mateos1, Monica Fernandez Castro5, Blanca Garcia-Magallon1, Maria Hildegarda Godoy Tundidor1, Carolina Merino1, JESUS SANZ SANZ1, Jose Luis Andreu1 and Jose Campos1, 1Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 2Hospital Universitario Ramon y Cajal, Madrid, Spain, 3Hospital Universitario Ramón y Cajal, Madrid, Spain, 4Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain, 5Puerta de Hierro Hospital, Madrid, Spain

    Background/Purpose: Anti-transcriptional intermediary factor 1γ (anti-TIF 1γ) antibody is robustly linked with malignancy-associated dermatomyositis (DM) in adults, but its specificity varies widely between series. TIF…
  • Abstract Number: 1860 • ACR Convergence 2022

    Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Activates Diverse Cell-specific Pathways in Whole Blood Leukocytes in Dermatomyositis

    Nilesh Kodali1, Thomas Vazquez2, DeAnna Diaz3, Josh Dan4, Grant Sprow5, Rohan Dhiman6, Mariko Ogawa-Momohara7, Muhammad Bashir6, Meena Sharma8 and Victoria Werth9, 1New Jersey Medical School, Coppell, TX, 2FIU Wertheim College of Medicine, Virginia Beach, VA, 3Philadelphia College of Medicine, Philadelphia, PA, 4Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 5Albert Einstein College of Medicine, Philadelphia, PA, 6University of Pennsylvania, Philadelphia, PA, 7Nagoya University Graduate School of Medicine, Nagoya, Japan, 8Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 9University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

    Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease that affects the skin and muscle. Lenabasum, a cannabinoid type 2 receptor (CB2R) agonist, has been developed…
  • Abstract Number: 1872 • ACR Convergence 2022

    Outcome of Idiopathic Inflammatory Myositis Patients Who Received Rituximab: A Single Centre Retrospective Study

    Fahidah Alenzi1, Shirish Sangle2 and Sanna Giovanni2, 1Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia, 2Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

    Background/Purpose: Idiopathic inflammatory myositis (IIM) includes a spectrum of a rare autoimmune disease characterized by proximal muscle weakness, variable skin manifestation and extra muscular manifestations.…
  • Abstract Number: 1377 • ACR Convergence 2022

    Mental Health Screening in Juvenile Myositis: Preliminary Analysis of a Multicenter Pilot Study

    Kaveh Ardalan1, Lindsay Olson1, Jeffrey Dvergsten2, Ann Reed1, Alison Manning1, Gary Maslow1, Aruna Rikhi1, Brian Feldman3, ashley Danguecan4, Sarah Mossad4, Luana Flores Pereira4, Susan Shenoi5, Stacey Haynes5, Joanna Patten5 and Andrea Knight6, 1Duke University School of Medicine, Durham, NC, 2Duke University Hospital, Durham, NC, 3Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 4The Hospital for Sick Children, Toronto, ON, Canada, 5Seattle Children's Hospital and Research Center / University of Washington, Seattle, WA, 6The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Qualitative studies in juvenile myositis (JM) suggest high rates of emotional distress but the prevalence of mental health comorbidities is not well described. We…
  • « Previous Page
  • 1
  • …
  • 445
  • 446
  • 447
  • 448
  • 449
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology